Biogen Halts Aducanumab Development and Marketing, Signaling a Pivotal Shift in Alzheimer’s Treatment Strategy
Pharmaceutical giant Biogen announced this week its decision to discontinue the development and marketing of aducanumab, commercially known as Aduhelm, an Alzheimer’s drug that garnered both groundbreaking attention and significant…
Alzheimer’s Research UK Bolsters Leadership with Four Eminent Trustees to Accelerate "Towards A Cure" Strategy
Alzheimer’s Research UK, the nation’s leading dementia research charity, officially announced on Wednesday, February 7, 2024, the appointment of four distinguished individuals to its Board of Trustees. These new Trustees,…
Erectile Dysfunction Drugs Linked to Reduced Alzheimer’s Risk in Landmark UCL Study
New research from University College London (UCL), published in the online issue of the medical journal Neurology, has revealed a compelling association between the use of drugs designed to treat…
New Alzheimer’s Treatments Lecanemab and Donanemab: A Turning Point Amidst NHS Readiness Concerns
The landscape of Alzheimer’s disease treatment is on the cusp of a transformative shift, heralded by the potential arrival of two pioneering drugs, lecanemab and donanemab. Recent BBC Panorama episode,…
European Regulators Decline Approval for Lecanemab, Citing Insufficient Benefit Against Risks
Brussels, Belgium – In a significant decision that underscores the global complexities of approving novel treatments for early Alzheimer’s disease, an expert committee for the European Medicines Agency (EMA) has…
Alzheimer’s Research UK Renews Flagship Drug Discovery Alliance with Landmark £45 Million Investment, Signalling a New Era in Dementia Research
In a pivotal moment for global dementia research, Alzheimer’s Research UK (ARUK) has announced the significant renewal of its flagship Drug Discovery Alliance (DDA), committing up to £45 million in…
European Medicines Agency Rejects Lecanemab for Early Alzheimer’s Disease, Citing Insufficient Benefit-Risk Profile.
The European Medicines Agency (EMA), through its expert Committee for Medicinal Products for Human Use (CHMP), has delivered a significant blow to the global fight against Alzheimer’s disease, announcing its…












